Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, CAR-T, CD19 Apr 08 | 2022Thoughts on Breyanzi’s sNDA Acceptance in Japan for 2L LBCLAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Apr 04 | 2022Thoughts on Yescarta's FDA Approval in 2L LBCLAccess Free BlastFree
Posted in: Autologous, CD19 Apr 01 | 2022Yescarta Becomes the First Approved CAR-T for 2L LBCL in the USAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Mar 25 | 2022CHMP Adopts Positive Opinions for Kymriah and Carvykti; Tecartus Absent From March’s CHMP HighlightsAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Mar 25 | 2022Breyanzi’s sNDA Accepted in Japan for 2L DLBCLAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Mar 24 | 2022Thoughts on Chinese CAR-T Ambitions after Lilly CRL and ODACAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, TCR Mar 23 | 2022TCR2 Tx Submits Gavo-cel's Protocol Amendment to the FDA; TC-510’s IND Filed in Q1 2022; TCR2 Tx Q4 2021 Earnings ReleaseAccess Free BlastFree
Posted in: Autologous, TCR Mar 22 | 20222seventy Extends Its Cash Runway Into 2025; Could Abecma Receive a ≥3L MM Approval Between 2023 – 2024? 2seventy Q4 2021 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Mar 21 | 2022Could Carvykti Receive a CHMP Positive Opinion This Week? Type II Variations for Tecartus and Kymriah Listed in March’s CHMP AgendaAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Mar 21 | 2022Legend Continues to Expand the CARTITUDE Program; Will Carvykti Receive Approval in Japan by September 2022? Legend Receives Official FDA Clinical Hold Letter for LB1901; Legend Q4 2021 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Mar 16 | 2022Thoughts on Carvykti’s Label, Price, Manufacturing, and TAT Compared to AbecmaAccess Free BlastFree
Posted in: Autologous, TCR Mar 15 | 2022Afami-cel's BLA Filing Anticipated During Q4 2022; MAGE-A4 Allogeneic Platform On Track for IND Submission in 2023; No Major Updates for Precision BioSciences; Adaptimmune and Precision Q4 2021 Earnings SummariesAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Mar 14 | 2022Gracell’s GC012F US IND Submission Delayed to H2 2022; Assets Targeting Solid Tumors to Enter the Clinic in 2022; Gracell Expands Operations in the US; Gracell Q4 2021 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T Mar 11 | 2022Poseida's Upcoming Clinical Updates for 2022; Poseida Seeks Further Partners to Develop Their Novel Platforms; Poseida Q4 2021 Earnings SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19 Mar 10 | 2022Obe-cel's US Filing Delayed to H2 2023; Stevenage Manufacturing Site to be Operational by Mid-2023; Autolus Q4 2021 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, CD123, CD22 Mar 04 | 2022Cellectis’s Raleigh GMP Facility is Fully Operational; Cellectis to Prioritize Clinical Programs During 2022; Solid Tumor Programs Deprioritized in 2022; Cellectis Q4 2021 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Feb 28 | 2022Carvykti Approved by FDA in R/R MM After Four Lines of Previous TherapyAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 25 | 2022Yescarta Absent From February’s CHMP HighlightsAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, TCR Feb 24 | 2022Poseida’s P-PSMA-101 Demonstrates Encouraging Efficacy in mCRPC; Upcoming Milestones for Poseida’s Allogeneic Platform; Poseida Seeking to Partner Their Emerging Technologies; Poseida’s R&D Day SummaryAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19 Feb 24 | 2022ALLO-501A Pivotal Trial on Track to Initiate in Mid-2022; Which BCMA Program Will Be Prioritized? New Registrational ALLO-647 Trial Anticipated for Mid-2022; Allogene Q4 2021 Earnings Call SummaryAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.